Literature DB >> 8785390

In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function.

N Topley1, D Kaur, M M Petersen, A Jörres, J D Williams, D Faict, C J Holmes.   

Abstract

The inclusion of bicarbonate in the formulation of peritoneal dialysis solutions may avoid the in vitro impairment of certain cell functions seen with acidic lactate-based fluids. The supranormal physiological levels of HCO3- and PCO2 inherent in such formulations may, however, not be biocompatible. This study compared the in vitro biocompatibility of a pH 5.2 lactate-based formulation with formulations containing either 40 mM lactate at pH 7.4, 38 mM HCO3- at pH 6.8 (PCO2 at approximately 240 mm Hg) or 7.4 (PCO2 at approximately 60 mm Hg), and 25 mM HCO3- plus 15 mM lactate at pH 6.8 (PCO2 at approximately 160 mm Hg) or 7.4 (PCO2 at approximately 40 mm Hg). Significant release of lactate dehydrogenase or decreases in ATP content by human peritoneal mesothelial cells (HPMC) and human peripheral polymorphonuclear leukocytes (PMN) after a 30-min exposure to each test solution was only seen with the pH 5.2 lactate-based fluid. The ATP content of HPMC exposed to this fluid returned to control levels after 30 min of recovery in M199 control medium but showed a trend toward decreasing ATP content at 240 min. Similarly, interleukin (IL)-1 beta-induced IL-6 synthesis by HPMC was also only significantly reduced by the pH 5.2 lactate solution. PMN chemiluminescence was unaffected by 30-min exposure to all test solutions except for the pH 5.2 lactate formulation. Staphylococcus epidermidis phagocytosis was reduced to between 46 to 57% of control with all test solutions except the pH 5.2 lactate solution, which further suppressed the chemiluminescence response to 17% of control. These data suggest that short exposure to supranormal physiological levels of HCO3- and PCO2 does not impair HPMC or PMN viability and function. Furthermore, neutral pH lactate-containing solutions show equivalent biocompatibility to bicarbonate-based ones.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8785390     DOI: 10.1681/ASN.V72218

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  11 in total

Review 1.  New peritoneal dialysis fluids: practical use for children.

Authors:  Cornelis H Schröder
Journal:  Pediatr Nephrol       Date:  2003-11       Impact factor: 3.714

2.  Buffer-dependent regulation of aquaporin-1 expression and function in human peritoneal mesothelial cells.

Authors:  Yihui Zhai; Jacek Bloch; Meike Hömme; Julia Schaefer; Thilo Hackert; Bärbel Philippin; Vedat Schwenger; Franz Schaefer; Claus P Schmitt
Journal:  Pediatr Nephrol       Date:  2012-03-01       Impact factor: 3.714

3.  The effect of peritoneal rest in combination therapy of peritoneal dialysis and hemodialysis: using the cultured human peritoneal mesothelial cell model.

Authors:  Tadashi Tomo; Eiji Okabe; Kazuhiro Matsuyama; Tomohiko Iwashita; Keiko Yufu; Masaru Nasu
Journal:  J Artif Organs       Date:  2005       Impact factor: 1.731

4.  Interleukin-1 receptor-mediated inflammation impairs the heat shock response of human mesothelial cells.

Authors:  Klaus Kratochwill; Michael Lechner; Anton Michael Lichtenauer; Rebecca Herzog; Hans Christian Lederhuber; Christian Siehs; Michaela Endemann; Bernd Mayer; Andreas Rizzi; Christoph Aufricht
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

5.  Interference of peritoneal dialysis fluids with cell cycle mechanisms.

Authors:  Janine Büchel; Maria Bartosova; Gwendolyn Eich; Timo Wittenberger; Ludger Klein-Hitpass; Sonja Steppan; Thilo Hackert; Franz Schaefer; Jutta Passlick-Deetjen; Claus P Schmitt
Journal:  Perit Dial Int       Date:  2014-07-31       Impact factor: 1.756

6.  Effect of the dialysis fluid buffer on peritoneal membrane function in children.

Authors:  Claus Peter Schmitt; Barbara Nau; Gita Gemulla; Klaus E Bonzel; Tuula Hölttä; Sara Testa; Michel Fischbach; Ulrike John; Markus J Kemper; Anja Sander; Klaus Arbeiter; Franz Schaefer
Journal:  Clin J Am Soc Nephrol       Date:  2012-11-02       Impact factor: 8.237

7.  Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.

Authors:  Kunio Kawanishi; Kazuho Honda; Misao Tsukada; Hideaki Oda; Kosaku Nitta
Journal:  Perit Dial Int       Date:  2012-11-01       Impact factor: 1.756

Review 8.  Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.

Authors:  Mufazzal Ahmad; Hemal Shah; Theodori Pliakogiannis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006-09-27       Impact factor: 2.266

9.  Functional and Transcriptomic Characterization of Peritoneal Immune-Modulation by Addition of Alanyl-Glutamine to Dialysis Fluid.

Authors:  Rebecca Herzog; Lilian Kuster; Julia Becker; Tobias Gluexam; Dietmar Pils; Andreas Spittler; Manoj K Bhasin; Seth L Alper; Andreas Vychytil; Christoph Aufricht; Klaus Kratochwill
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

Review 10.  Animal Models of Peritoneal Dialysis: Thirty Years of Our Own Experience.

Authors:  Krzysztof Pawlaczyk; Ewa Baum; Krzysztof Schwermer; Krzysztof Hoppe; Bengt Lindholm; Andrzej Breborowicz
Journal:  Biomed Res Int       Date:  2015-07-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.